Eltrekibart

DRUG4 trials

Sponsors

Eli Lilly & Co., Eli Lilly and Company

Conditions

Hidradenitis SuppurativaModerate to Severe Hidradenitis SuppurativaUlcerative ColitisUlcerative Colitis Chronic

Phase 2

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

CompletedNCT06046729

Eli Lilly and CompanyHidradenitis Suppurativa

Start: 2023-10-23End: 2026-08-17Updated: 2026-08-21

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Active, not recruitingCTIS2023-505608-43-00

Eli Lilly & Co.Moderate to Severe Hidradenitis Suppurativa

Start: 2024-07-04Target: 90Updated: 2025-03-24

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

RecruitingNCT06598943

Eli Lilly and CompanyUlcerative Colitis, Ulcerative Colitis Chronic

Start: 2024-10-10End: 2028-09-01Target: 143Updated: 2026-07-30

I7P-MC-DSAG - An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

RecruitingCTIS2023-507853-13-00

Eli Lilly & Co.Ulcerative Colitis

Start: 2025-02-25Target: 605Updated: 2025-11-11